Literature DB >> 31123831

Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep and Mood.

Megan Alston1, Sean W Cain2, Shantha M W Rajaratnam3.   

Abstract

Melatonin and melatonin agonists offer novel treatments for sleep and mood disorders, particularly where circadian misalignment is also present. The therapies offer both phase-shifting and sleep-promoting effects and have shown potential to treat advanced and delayed sleep-wake phase disorder, non-24-h sleep-wake cycle, jetlag, shift work disorder, insomnia, seasonal affective disorder and major depressive disorder.

Entities:  

Keywords:  Agomelatine; Circadian rhythm; Circadin; Major depressive disorder; Melatonin; Melatonin agonist; Mood; Ramelteon; Sleep; Tasimelteon

Mesh：

Substances：

Year:  2019        PMID： 31123831     DOI： 10.1007/164_2018_139

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN： 0171-2004


  4 in total

Review 1.  Melatonin in Endometriosis: Mechanistic Understanding and Clinical Insight.

Authors:  Yiran Li; Sze-Wan Hung; Ruizhe Zhang; Gene Chi-Wai Man; Tao Zhang; Jacqueline Pui-Wah Chung; Lanlan Fang; Chi-Chiu Wang
Journal:  Nutrients       Date:  2022-10-01       Impact factor: 6.706

Review 2.  Evaluation and Management of Sleep and Circadian Rhythm Disturbance in Cancer.

Authors:  Diwakar D Balachandran; Michelle A Miller; Saadia A Faiz; Sriram Yennurajalingam; Pasquale F Innominato
Journal:  Curr Treat Options Oncol       Date:  2021-07-02

Review 3.  Importance of Melatonin in Assisted Reproductive Technology and Ovarian Aging.

Authors:  Hiroshi Tamura; Mai Jozaki; Manabu Tanabe; Yuichiro Shirafuta; Yumiko Mihara; Masahiro Shinagawa; Isao Tamura; Ryo Maekawa; Shun Sato; Toshiaki Taketani; Akihisa Takasaki; Russel J Reiter; Norihiro Sugino
Journal:  Int J Mol Sci       Date:  2020-02-08       Impact factor: 5.923

4.  Mice lacking melatonin MT2 receptors exhibit attentional deficits, anxiety and enhanced social interaction.

Authors:  David M Thomson; Emma J Mitchell; Rebecca L Openshaw; Judith A Pratt; Brian J Morris
Journal:  J Psychopharmacol       Date:  2021-07-24       Impact factor: 4.153
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.